At its meeting on 8 July 2024, the Transparency Council adopted opinion No. 65/2024 on the legitimacy of issuing approvals for the reimbursement of the drug Glycosade for the indications: glycogenosis and glycogenosis type Ia, Ib, III, IV, VI, IX, XI, III-VI-IX
Publication of the position >>